Activin and Inhibin

Lansoprazole-d 4 is a deuterium labeled Lansoprazole. Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid.Form:SolidIC50&amp: Target:Proton Pump Inhibitor.

Lansoprazole-d 4 is a deuterium labeled Lansoprazole. Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid.Form:SolidIC50&amp: Target:Proton Pump Inhibitor.

Lansoprazole-d 4 is a deuterium labeled Lansoprazole. Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid.Form:SolidIC50&amp: Target:Proton Pump Inhibitor.

Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate ( HY-16274 ). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapyIn VitroLapaquistat inhibits cholesterol

Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate ( HY-16274 ). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapyIn VitroLapaquistat inhibits cholesterol

Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate ( HY-16274 ). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapyIn VitroLapaquistat inhibits cholesterol

Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate ( HY-16274 ). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapyIn VitroLapaquistat inhibits cholesterol

Lartesertib (M4076) is a potent inhibitor of serine/threonine protein kinase ATM (extracted from patent WO2022058351A1)Form:SolidIC50&amp: Target:ATM.

Lartesertib (M4076) is a potent inhibitor of serine/threonine protein kinase ATM (extracted from patent WO2022058351A1)Form:SolidIC50&amp: Target:ATM.

Lartesertib (M4076) is a potent inhibitor of serine/threonine protein kinase ATM (extracted from patent WO2022058351A1)Form:SolidIC50&amp: Target:ATM.

Lartesertib (M4076) is a potent inhibitor of serine/threonine protein kinase ATM (extracted from patent WO2022058351A1)IC50&amp: Target:ATM.

LAS101057 is a potent, selective, and orally efficacious A2B receptor antagonist.In VivoAt 3 mg/kg, LAS101057 is active in preventing Acetyl-β-methylcholine-induced AHR, and at 10 mg/kg it inhibits AHR to Acetyl-β-methylcholine to a level virtually